Practical Considerations for Use of Direct Oral Anticoagulants in Children
Direct oral anticoagulants (DOACs) provide an attractive alternative for the management and prevention of thrombosis in pediatric patients. With multiple ongoing and published pediatric trials and recent regulatory approval of dabigatran and rivaroxaban, the landscape of pediatric anticoagulation is...
Main Authors: | Hilary Whitworth, Leslie Raffini |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-04-01
|
Series: | Frontiers in Pediatrics |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fped.2022.860369/full |
Similar Items
-
Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran
by: Maha Al-Ghafry, et al.
Published: (2022-10-01) -
Current Antithrombotic Therapy Strategies in Children with a Focus on Off-Label Direct Oral Anticoagulants—A Narrative Review
by: Stefana Maria Moisa, et al.
Published: (2022-07-01) -
Challenges in Management of VTE in Children With Cancer: Risk Factors and Treatment Options
by: Nasrin Samji, et al.
Published: (2022-04-01) -
Direct-acting oral anticoagulants in antiphospholipid syndrome
by: T. M. Reshetnyak, et al.
Published: (2021-01-01) -
DIRECT ORAL ANTICOAGULANTS
by: I. Tzoran, et al.
Published: (2016-06-01)